Advertisement
AXON vs TECH
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Bio-Techne (TECH) Stock Comparison
Key Takeaways
- AXON (Axon Enterprise) is a high-growth public safety technology company, yet its shares have pulled back sharply from 2025 highs despite accelerating revenue and recurring-revenue growth.
- TECH (Bio-Techne) is a life sciences tools provider that has agreed to be acquired by Merck KGaA for $73 per share in cash, anchoring its stock near the deal price.
- The two companies occupy entirely different sectors — industrials and public safety software versus healthcare and life sciences — making this a contrast in growth style rather than a like-for-like peer matchup.
- AXON carries a premium valuation and elevated volatility, while TECH trades as a lower-growth, lower-volatility name with a defined takeover catalyst.
- Relative performance and risk profiles diverge sharply: AXON faces execution and valuation risk, while TECH faces deal-completion risk and near-term organic growth headwinds.
Introduction
Investors evaluating AXON and TECH are weighing two very different investment profiles. AXON, a fast-growing provider of public safety hardware and software, has recently seen its valuation reset after a period of rapid appreciation. TECH, a life sciences reagent and diagnostics supplier, is now largely a merger-arbitrage situation following an announced acquisition. This stock comparison is most relevant for traders and investors seeking to understand how growth momentum, valuation, and event-driven catalysts shape market positioning across two unrelated industries.
AXON Overview and Recent Performance
Axon Enterprise develops public safety technology, including TASER devices, body-worn cameras, cloud evidence software, and AI-driven tools such as automated report drafting and drone-based response systems. The company has continued to report strong fundamentals in recent quarters, with revenue expanding roughly 35% year over year and annual recurring revenue (ARR) — the predictable subscription revenue the business generates each year — growing near 40%, supported by a net revenue retention rate above 120%.
Despite this operational momentum, AXON shares have fallen meaningfully from their 2025 peak and remain down substantially year to date. The pullback has coincided with a broader de-rating of software and software-like businesses, as investors reassessed premium valuations. AXON also raised more than $1 billion through zero-coupon convertible notes, a move that supports its balance sheet but introduces potential dilution. Analysts have trimmed price targets while generally maintaining a favorable long-term view, and the stock continues to trade with above-average volatility relative to the broader market.
TECH Overview and Recent Performance
Bio-Techne is a global life sciences company that supplies specialized proteins, antibodies, reagents, analytical instruments, and diagnostics used by researchers and biopharmaceutical firms. Its portfolio spans Protein Sciences and Diagnostics and Spatial Biology segments. Recent results have been mixed: fiscal-year revenue was roughly flat, with continued strength from large pharmaceutical customers offset by softer spending among emerging biotechnology firms.
The most significant development for TECH in recent months is an agreement to be acquired by Merck KGaA of Germany for $73 per share in cash, valuing the company at approximately $11.3 billion. Because the stock now trades near the agreed cash price, its day-to-day movement is driven more by merger-completion expectations than by operating fundamentals. The company has also streamlined its brand structure and continues to emphasize growth vectors such as spatial biology and GMP (good manufacturing practice) proteins, but its shares now largely reflect the pending transaction rather than standalone performance.
Trending AI Robots
For traders who prefer a data-driven, automated approach, Tickeron's Trending AI Robots page highlights a curated selection of AI trading bots drawn from a much larger library of automated strategies. These bots apply different trading styles, timeframes, strategies, and risk parameters across thousands of tickers, with performance statistics that vary widely. Because not every bot suits every market condition, Tickeron surfaces only the most relevant and best-performing strategies in its Trending section, helping users identify the robots currently aligned with prevailing market dynamics. Browsing the page offers a practical way to compare how different automated approaches are positioned across names like AXON and TECH.
Head-to-Head Comparison
The clearest contrast between these two names is their business model and growth trajectory. AXON is a momentum-oriented compounder that pairs hardware with sticky, high-retention software subscriptions, producing double-digit revenue growth but a premium valuation and considerable share-price swings. TECH is a lower-growth, research-driven franchise whose near-term story is dominated by a cash takeover bid, which caps upside near the offer price while providing downside protection relative to the broader market.
Sector exposure also differs materially. AXON is tied to government and law-enforcement budgets and the industrial/public safety technology complex, whereas TECH depends on research funding cycles, biopharmaceutical R&D spending, and diagnostic demand. Risk factors diverge accordingly: AXON's risks center on execution, valuation compression, and potential share dilution, while TECH's risks center on merger approval, integration, and sluggish organic growth in its end markets. Market sentiment reflects these differences, with AXON experiencing a repricing of a formerly high-flying growth stock and TECH trading as a relatively stable, event-driven holding.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor AXON for its stronger trend consistency and clearer standalone growth catalysts, while recognizing that its elevated volatility and valuation present meaningful downside risk. TECH, by contrast, offers a more defined near-term outcome through its pending acquisition but limited independent upside. The balance of evidence suggests AXON holds a relative advantage on growth momentum and market positioning, though TECH's lower volatility and event-driven catalyst could appeal under different market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Buy and TECH is a Hold.
AXON in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 16, 2026
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 33 cases where AXON's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AXON's RSI Oscillator exited the oversold zone, 20 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on AXON as a result. In 62 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 29 of 39 cases over the following month. The odds of a continued upward trend are 74%.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 51 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.457) is normal, around the industry mean (5.060). AXON has a moderately high P/E Ratio (173.186) as compared to the industry average of (17.792). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.058) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
TECH in downward trend: price may decline as a result of having broken its higher Bollinger Band on October 26, 2026
TECH broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 35 similar instances where the stock broke above the upper band. In 29 of the 35 cases the stock fell afterwards. This puts the odds of success at 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TECH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on TECH as a result. In 61 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
Following a +0.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where TECH advanced for three days, in 190 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 94 of 231 cases where TECH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 41%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TECH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.405) is normal, around the industry mean (3.162). TECH has a moderately high P/E Ratio (62.103) as compared to the industry average of (-1.064). Projected Growth (PEG Ratio) (2.110) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (131.622) among similar stocks. P/S Ratio (9.346) is also within normal values, averaging (439.647).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TECH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AXON | TECH | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 94 Overvalued | |
PROFIT vs RISK RATING 1..100 | 67 | 100 | |
SMR RATING 1..100 | 81 | 74 | |
PRICE GROWTH RATING 1..100 | 61 | 36 | |
P/E GROWTH RATING 1..100 | 51 | 91 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AXON's Valuation (92) in the Biotechnology industry is in the same range as TECH (94). This means that AXON’s stock grew similarly to TECH’s over the last 12 months.
AXON's Profit vs Risk Rating (67) in the Biotechnology industry is somewhat better than the same rating for TECH (100). This means that AXON’s stock grew somewhat faster than TECH’s over the last 12 months.
TECH's SMR Rating (74) in the Biotechnology industry is in the same range as AXON (81). This means that TECH’s stock grew similarly to AXON’s over the last 12 months.
TECH's Price Growth Rating (36) in the Biotechnology industry is in the same range as AXON (61). This means that TECH’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (51) in the Biotechnology industry is somewhat better than the same rating for TECH (91). This means that AXON’s stock grew somewhat faster than TECH’s over the last 12 months.
| AXON | TECH | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 71% | N/A |
| Stochastic ODDS (%) | 3 days ago 74% | 3 days ago 63% |
| Momentum ODDS (%) | 3 days ago 82% | 3 days ago 69% |
| MACD ODDS (%) | 3 days ago 74% | N/A |
| TrendWeek ODDS (%) | 3 days ago 76% | 3 days ago 60% |
| TrendMonth ODDS (%) | 3 days ago 73% | 3 days ago 55% |
| Advances ODDS (%) | 6 days ago 74% | 4 days ago 66% |
| Declines ODDS (%) | 14 days ago 70% | 10 days ago 72% |
| BollingerBands ODDS (%) | 3 days ago 85% | 3 days ago 83% |
| Aroon ODDS (%) | 3 days ago 68% | 3 days ago 41% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while TECH’s FA Score has 0 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- TECH’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 5 TA indicator(s) are bullish while TECH’s TA Score has 3 bullish TA indicator(s).
- AXON’s TA Score: 5 bullish, 4 bearish.
- TECH’s TA Score: 3 bullish, 3 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а +1.76% price change this week, while TECH (@Biotechnology) price change was +0.15% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +2.04%. For the same industry, the average monthly price growth was -10.06%, and the average quarterly price growth was -17.31%.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.
Reported Earning Dates
AXON is expected to report earnings on Nov 05, 2026.
TECH is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Aerospace & Defense (+2.04% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (+0.20% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
TECH and
Correlation & Price change
A.I.dvisor indicates that over the last year, TECH has been loosely correlated with AXON. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if TECH jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To TECH | 1D Price Change % | ||
|---|---|---|---|---|
| TECH | 100% | -0.07% | ||
| AXON - TECH | 61% Loosely correlated | -2.35% | ||
| ARRY - TECH | 44% Loosely correlated | -4.78% | ||
| VCYT - TECH | 43% Loosely correlated | -4.14% | ||
| RCKT - TECH | 42% Loosely correlated | -3.94% | ||
| NVO - TECH | 37% Loosely correlated | +2.20% | ||
More | ||||